Cargando…
Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma
Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic RCC (mRCC) is stil...
Autores principales: | Li, Xiezhao, Xu, Peng, Wang, Chongshan, Xu, Naijin, Xu, Abai, Xu, Yawen, Sadahira, Takuya, Araki, Motoo, Wada, Koichiro, Matsuura, Eiji, Watanabe, Masami, Zheng, Junxia, Sun, Pinghua, Huang, Peng, Nasu, Yasutomo, Liu, Chunxiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400575/ https://www.ncbi.nlm.nih.gov/pubmed/28416753 http://dx.doi.org/10.18632/oncotarget.15505 |
Ejemplares similares
-
Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer
por: Lin, Wenfeng, et al.
Publicado: (2021) -
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer
por: Xu, Naijin, et al.
Publicado: (2019) -
Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity
por: Xu, Naijin, et al.
Publicado: (2020) -
Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment
por: Lin, Wenfeng, et al.
Publicado: (2021) -
Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma
por: Lin, Wenfeng, et al.
Publicado: (2022)